INTRODUCTION
Vascular dementia (VaD) is the impairment of memory and cognitive functioning resulting from cerebrovascular disease (CVD) such as infarcts and leukoaraiosis. Although VaD is considered to be the second most common cause of cognitive impairment after Alzheimer's disease (AD) in the elderly, controversy remains concerning the terminology, classification, and diagnostic criteria of VaD. Cognitive status after a stroke is unstable and wide variability in the rates of cognitive impairment and dementia after stroke is reported, regardless of study duration or methods. 1 
EPIDEMIOLOGY AND RISK FACTORS
It is estimated that 6% to 10% of people over the age of 65 have dementia and up to 60% of patients with AD likely have an overlap with VaD. VaD alone is presumed to account for nearly 20% to 40% of dementia cases. 2 Seventyfive percent of all strokes occur in individuals older than 65 years. 3 In poststroke patients, age is the greatest risk factor for the development of VaD. 4 Although the incidence rate of VaD varies considerably depending on the study methodology and criteria used, in one study, the risk of dementia with stroke was higher for those older than 80 years of age (odds ratio [OR]=12.7) or aged 70-79 years (OR=3.0) than for those aged 60-69 years, for those with 8 or fewer years of education versus those with 13 or more years (OR= 4.1), for major hemispheric stroke versus posterior fossa (OR=3.0), for those with diabetes mellitus (OR=1.8), for anterior/posterior cerebral artery distribution versus other vascular territories (OR=1.7), and for those with prior stroke (OR=1.7). 5 Research has established a strong relationship between age, low education level, and poststroke dementia as well as vascular risk factors (e.g., hypertension, diabetes, hyperlipidemia, smoking). 3, 5 Ethnic comparisons in the Cardiovascular Health Study showed nearly twofold higher incidence rates among African Americans than in whites. 6 Men, those of Asian descent, and older people have a tendency for a higher risk of VaD. 5, 6 VaD is considered to result from interactions between vascular etiologies, changes in the brain, host factors, and cognition. 7 Some studies have found that infarcts may precipitate dementia through an additive or synergistic relationship with AD neuropathology.
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CLASSIFICATION AND CLINICAL FEATURES OF VaD
Post-stroke dementia, which includes multi-infarct de- (Fig. 1) . MID is related to atherothrombotic strokes, cardiac embolic strokes, and major hemodynamic events. Typical clinical features of MID are focal neurological signs such as hemiparesis or sensory deficits and stepwise progression with cognitive impairment. The presence of 'patchy' or unequal cognitive deficits are only to be expected in MID where there are only very few (two or three) cortical infarcts. Strategic infarct dementia is caused by isolated infarcts in regions that are important for cognition of the brain, such as the thalamus, hippocampus, caudate, or genu of the internal capsule (Fig. 2) . It is characterized by the abrupt onset of cognitive or behavioral changes, which vary depending on the infarct location. Most VaD results from multi-infarcts where cortical damage is responsible for cognitive impairment. However, this is now known to be a relatively rare pattern of disease in VaD and in the far more common subcortical form of VaD (SVD), a history of stroke may be absent in up to 40%. 12 The primary types of brain lesions in SVD are lacunar infarcts and ischemic white matter lesions (WMLs) (Fig. 3 ). Therefore, accumulation of small infarcts in the deep white matter and gray matter may lead to SVD. Lacunar infarcts represent approximately 25% of symptomatic ischemic strokes. 12 WMLs have been associated with age, hypertension, diabetes, metabolic syndrome, microvascular retinopathy, elevated homocysteine levels, and ischemic heart diseases. 13 The onset of SVD is insidious in over half of patients and the course is usually continuous and slowly progressive. 13, 14 Neurological symptoms and signs related to SVD include cognitive deterioration, gait disturbance (imbalance, fall, short-stepped gait), urinary dysfunction, and dysarthria. Behavioral and cognitive changes include mental slowness (bradyphrenia), emotional lability, personality changes, and depression. 15 Depression is common in VaD, occurring in up to 20% of cases, and is disproportionately prominent in those cases with small amounts of infarction. It may be particularly related to frontal deep white matter lesions. The primary pathophysiological mechanism underlying SVD seems to be vessel wall damage in the long penetrating arterioles that drain into the white matter, with subsequent white matter degeneration and occurrence of lacune.
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Orthostatic hypotension and blood pressure variability may play a role in hypoperfusion dementia or WMLs. 19 Proposed mechanisms for this role include nocturnal hypotension superimposed upon limited perfusion reserve and impaired vasoreactivity producing partial ischemia leading to incomplete infarction. 20 Neuropsychological tests used in the assessment of AD such as the Mini-Mental State Examination (MMSE) are commonly used to evaluate cognition in VaD but are not appropriate tools in patients with VaD because neuropsychological characteristics in both subtypes of dementia are not similar. VaD predominantly involves deficits in executive functioning, whereas AD involves earlier and more significant memory impairment.
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Instruments that include assessment of frontal, executive, and subcortical function are required for the diagnosis of VaD.
Because the pathogenesis, risk factors, and comorbidities for VaD are similar to those for AD, it is sometimes difficult to differentiate the two. 13 The major clinical differences between VaD and AD are summarized in Table 1 .
DIAGNOSIS
The diagnosis of VaD is developed by considering clinical, imaging, and pathological findings. Given the heterogeneity of the VaD phenotype, large, uniform data sets are necessary to unravel the links between CVD and cognitive impairment. Three basic elements for a diagnosis of VaD are 1) evidence of dementia or cognitive impairment, 2) evidence of CVD, and 3) evidence of a casual relationship between cognitive impairment and CVD. Although there are no uniform diagnostic criteria for VaD, guidelines for interpreting neuroimaging findings have been incorporated into recent criteria for the clinical diagnosis of VaD. The main set of criteria for the clinical diagnosis of VaD are the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) 21 ; the International Classification of Diseases 10th version (ICD-10) 22 ; the State of California Alzheimer's Disease Diagnostic and Treatment Centers (ADDTC) criteria 23 ; and the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS-AIREN) criteria. 24 All the currently used clinical criteria are 'consensus criteria' derived from expert opinion based on prevailing knowledge and pathogenetic hypotheses of dementia. All are based on the ischemic infarct concept, with the NINDS-AIREN, DSM-IV, and ICD-10 also including hemorrhages. The DSM-IV criteria for VaD require focal neurological signs and symptoms or laboratory evidence of focal neurological damage clinically judged to be etiologically related to the disturbance, but the criteria lack neuroimaging guidelines. The ICD-10 criteria require unequal, patchy distribution of cognitive deficits, focal neurological signs, and significant CVD judged to be etiologically related to the dementia, but the shortcomings of these criteria include a lack of detailed etiological and neuroimaging guidelines. The ADDTC criteria are exclusive for ischemic VaD and require two or more ischemic strokes by history, neurological signs, or neuroimaging. The NINDS-AIREN criteria include definitions for the dementia syndrome, CVD, and their relationship. A relationship between dementia and CVD is inferred from the onset of dementia within 3 months following recognized stroke, or abrupt deterioration in cognitive functions, or fluctuating, stepwise progression of cognitive deficits. The NINDS-AIREN criteria had moderate to substantial inter-rater re- liability and were more specific (80%), although less sensitive (58%). 25 The various diagnostic criteria are neither perfect nor interchangeable and none of these criteria have the required sensitivity and specificity to identify patients with mixed VaD reliably. 26, 27 This accounts for the variations in published prevalence and incidence rates and in treatment outcomes. The heterogeneity in the clinical presentation of VaD is compounded by the lack of consensus regarding the pathologic diagnosis of VaD. The main features of the most commonly used clinical criteria for VaD are summarized in Table 2 .
NEUROIMAGING
Although neuroimaging is not required for diagnosis by all clinical references, it is recommended in patients with suspected VaD owing to a stroke history, vascular risk factors, or abnormal neurological examination. If CT shows significant evidence of vascular pathology, MRI is not necessary. However, MRI is more sensitive than CT for ischemic damage and vascular lesions. The absence of cerebral vascular lesions on CT or MRI excludes the diagnosis of VaD. Features on CT or MRI that are suggestive of VaD include cortical or subcortical infarctions, multiple lacunar strokes, and WMLs.
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PREVENTION AND TREATMENT
Because stroke is common and its risk factors are well defined and modifiable, it is reasonable to intensify efforts to control cardiovascular risk factors to reduce the population of stroke and VaD. Rigorous control of vascular risk factors is important in the primary and secondary prevention of VaD. In terms of specific treatment, the use of cholinesterase inhibitors and N-methyl-d-aspartate receptor antagonists for VaD has been evaluated. 29 Donepezil (Aricept) 5 mg to 10 mg per day showed improvement in AD Assessment Scale-Cognitive (ADAS-Cog) subscale scores. [30] [31] [32] Galantamine (Reminyl) has been studied for the treatment of VaD in two randomized, double-blind, placebo-controlled trials of 592 patients and 788 patients, respectively. ADAS-Cog score was a primary efficacy measure. At 26 weeks, there were improvements in galantamine-treated patients at doses of 16 mg to 24 mg per day. However, a significant percentage of patients dropped out owing to adverse events, particularly gastrointestinal effects. 33, 34 Rivastigmine (Exelon) was studied in a randomized, placebo-controlled trial of 710 patients and it was superior to placebo on the ADAS-Cog score as a primary efficacy measure, except in younger (age 50-75 years) patients. 35 Memantine (Ebixa) was studied for the treatment of VaD in two large trials and both trials concluded that memantine 20 mg per day improved ADAS-Cog scores.
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The therapeutic approach to VaD is summarized as 1) primary prevention with cardiovascular risk factor control, 2) correct diagnosis of VaD, 3) secondary stroke prevention with anti-platelet therapy, and 4) cholinesterase inhibitors or NMDA receptor antagonists. The principles of anti-dementia drugs for VaD are summarized below 
PROGNOSIS AND COMPLICATIONS
The prognosis of VaD varies considerably according to the criteria used to make the diagnosis. MID shortens life expectancy to about 50% of normal at 4 years from the initial evaluation. 39 About one-third of the most severely affected elderly die from complications of the dementia itself, one-third from cerebrovascular disease, 8% from other cardiovascular disease, and the rest from miscellaneous causes. 40 Overall, the effect of VaD on mortality is similar to or mildly worse than that of AD. 5 
CONCLUSIONS
VaD is characterized most commonly by subcortical frontal and executive dysfunction of cognitive impairment as opposed to the concept of amnesia-predominant AD. It may begin with very subtle deficits arising on the basis of leukoaraiosis or WMLs and proceeds through infarction to a more advanced state. Early identification of vascular cognitive impairment due to vascular brain damage as an early stage of VaD and proper management through modification of vascular risk factors especially in midlife are important for the prevention of VaD.
